Affordable Access

Access to the full text

Glatiramer acetate versus interferon beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients

Authors
  • Castelli-Haley, Jane1
  • Oleen-Burkey, Merry-Kay A.1
  • Lage, Maureen J.2
  • Johnson, Kenneth P.3
  • 1 Teva Neuroscience, Kansas City, Missouri, USA , Kansas City (United States)
  • 2 HealthMetrics Outcomes Research, Groton, Connecticut, USA , Groton (United States)
  • 3 University of Maryland, Baltimore, Maryland, USA , Baltimore (United States)
Type
Published Article
Journal
Advances in Therapy
Publisher
Springer Healthcare Communications
Publication Date
Jul 18, 2008
Volume
25
Issue
7
Identifiers
DOI: 10.1007/s12325-008-0077-z
Source
Springer Nature
Keywords
License
Yellow

Abstract

IntroductionWe compared the outcomes of multiple sclerosis (MS) patients treated with either glatiramer acetate (GA) (Copaxone®, Teva Pharmaceutical Industries, Israel) or interferon beta-1a for subcutaneous administration (IFN beta-1a-SC) (Rebif®, Merck Serono, Switzerland).MethodsData were obtained from i3’s Lab Rx Database from July 2001 to June 2006. We established an ‘intent-to-treat’ (ITT) cohort (n=845) of patients diagnosed with MS who began therapy on either GA (n=542) or IFN beta-1a-SC (n=303) and had continuous insurance coverage from 6 months before to 24 months after the date they began taking the medication. We also created a ‘continuous use’ (CU) cohort (n=410) of individuals who, in addition to the criteria listed above, used either GA or IFN beta-1a-SC within 28 days of the end of the 2-year-post period. Using multivariate regressions, we examined both the 2-year total direct medical costs and the likelihood of relapse associated with the use of these two MS medications. We defined relapse as either being hospitalised with a diagnosis of MS, or being diagnosed with MS during an outpatient visit and then prescribed steroids within a 7-day period. All regressions controlled a wide range of factors that have potentially affected outcomes.ResultsIn the ITT cohort, patients who started therapy on GA had a significantly lower 2-year risk of relapse (5.92% versus 10.89%; P=0.0305), as well as significantly lower 2-year total medical costs (US$41,786 versus US$49,030; P=0.0002). In the CU cohort, patients who used GA also had a significantly lower 2-year risk of relapse (1.94% versus 9.09%; P=0.0049) and significantly lower total medical costs (US$45,213 versus US$57,311; P<0.0001).ConclusionsResults indicate that, compared with the use of IFN beta-1a-SC, use of GA is associated with significantly lower probability of relapse as well as significantly lower 2-year total direct medical costs. In addition, these results are more pronounced among patients defined as continuous users.

Report this publication

Statistics

Seen <100 times